Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients

• Published in: Arthritis research & therapy Vol. 22; no. 1; p. 80
• Main Authors: Fujita, Yuya, Asano, Tomoyuki, Matsuoka, Naoki, Temmoku, Jumpei, Sato, Shuzo, Matsumoto, Haruki, Furuya, Makiko Yashiro, Suzuki, Eiji, Watanabe, Hiroshi, Kawakami, Atsushi, Migita, Kiyoshi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 15.04.2020; BioMed Central; BMC
• Subjects: Age; Aged; Anti-citrullinated peptide antibody; Anti-Citrullinated Protein Antibodies - blood; Arthritis; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - immunology; Autoimmune diseases; Biomarkers - blood; Blood tests; Comparative analysis; Development and progression; Enzyme-linked immunosorbent assay; Enzymes; Female; Galectin-9; Galectins - blood; Humans; Immune response; Immunoassay; Inflammation; Male; Medical research; Middle Aged; Pathogenesis; Patients; Retrospective Studies; Rheumatoid arthritis; Rheumatoid factor; T cell immunoglobulin domain and mucin-3; T cells; Japan; Galectin-9; T cell immunoglobulin domain and mucin-3; Anti-citrullinated peptide antibody; Rheumatoid arthritis
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-020-02158-3

Galectin-9 (Gal-9) is involved in the regulatory process of immune responses or inflammation. The aim of the present study is to characterize circulating Gal-9 in patients with rheumatoid arthritis (RA) and its relationship with RA disease activity and phenotype. A total of 116 RA patients and 31 age-matched healthy controls were included in this study. Disease activity of RA patients was determined by Disease Activity Score of 28 joint scoring system (DAS28-ESR). Levels of Gal-9 in serum were determined by enzyme-linked immunosorbent assay (ELISA). Serum levels of Gal-9 were significantly higher in patients with RA compared to those in controls (median 7577 pg/ml [interquartile range (IQR) 5570-10,201] versus 4738 pg/ml [IQR 4267-5630], p = 0.001). There were significant differences in serum Gal-9 between RA patients with and without RA-ILD (9606 pg/ml [IQR 8522-12,167] versus 7078 pg/ml [IQR 5225-9447], p < 0.001) or those with and without advanced joint damage (stage II-IV, 9606 pg/ml [IQR 8522-12,167] versus 7078 pg/ml [IQR 5225-9447], p < 0.001). Although serum levels of Gal-9 correlated with the titers of ACPA (r = 0.275, p = 0.002), levels of ACPA titers conferred the different relationship, between serum Gal-9 and inflammatory mediators or RA disease activity. Although Gal-9 was correlated with ACPA titers (r = 0.508, p = 0.002), there was no correlation between Gal-9 levels and erythrocyte sedimentation rate (ESR), matrix metalloproteinase-3 (MMP-3), or DAS28-ESR in RA patients with high titers of ACPA (> 200 U/ml). Conversely, Gal-9 was correlated with MMP-3 (r = 0.300, p = 0.007) or DAS28-ESR (r = 0.331, p = 0.004) but not with ACPA titer in RA patients with low titers of ACPA titers (< 200 U/ml). Serum levels of Gal-9 were increased in RA patients and associated with RA disease activity in RA patients without high titers of ACPA. The levels of ACPA titers may influence the values of circulating Gal-9 in RA patients with various clinical phenotypes. These data suggest that Gal-9 possessed the properties of pro-inflammatory or arthropathic biomarker under the status of ACPA titers.